IL7R
IL7R (Interleukin-7 receptor subunit alpha) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Leukaemia, Non-Hodgkin lymphoma and 5 more.
Overview
Receptor for interleukin-7. Also acts as a receptor for thymic stromal lymphopoietin (TSLP).
CIViC holds 3 clinical evidence items and 0 assertions across 3 variants. Open Targets scores its association with cancer at 0.70 (direct and indirect evidence; datatypes literature 0.98, animal model 0.42, genetic association 0.36, somatic mutation 0.86). IntOGen calls it a driver in 4 cohorts (3 activating, 1 loss-of-function), covering Acute Lymphoblastic Leukaemia, Oesophageal Adenocarcinoma, Hepatocellular Carcinoma, Stomach Adenocarcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · IL7R (Interleukin-7 receptor subunit alpha) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Leukaemia, Non-Hodgkin lymphoma and 5 more.
- 1 · What it is
IL7R (Interleukin-7 receptor subunit alpha) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Leukaemia, Non-Hodgkin lymphoma and 5 more.
- 2 · What goes wrong in cancer
Receptor for interleukin-7. Also acts as a receptor for thymic stromal lymphopoietin (TSLP).
- 3 · How drugs use it
No product in this corpus aims at IL7R yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:6024 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P16871 (protein name, function text, keywords and locations (REST API)); CIViC gene IL7R (3 evidence items, 0 assertions, 3 variants; diseases: T-cell Acute Lymphoblastic Leukaemia, Childhood B-cell Acute Lymphoblastic Leukaemia, B-lymphoblastic Leukaemia/lymphoma, BCR-ABL1-like (GraphQL API, CC0)); Open Targets ENSG00000168685 (association with cancer (MONDO_0004992) 0.70; per-cancer scores at or above 0.5: melanoma 0.57, acute lymphoblastic leukaemia 0.59, non-Hodgkin lymphoma 0.61, skin cancer 0.64, lung cancer 0.56, leukaemia 0.62 (GraphQL API, CC0)); IntOGen IL7R (driver in 4 cohorts (Act 3, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Receptor for interleukin-7. Also acts as a receptor for thymic stromal lymphopoietin (TSLP). Location: Cell membrane; Secreted (UniProt). Locus 5p13.2 (HGNC).
- Skin cancer: Open Targets association 0.64 with skin cancer (MONDO_0002898)
- Leukaemia: Open Targets association 0.62 with leukaemia (MONDO_0005059)
- Non-Hodgkin lymphoma: Open Targets association 0.61 with non-Hodgkin lymphoma (MONDO_0018908)
- Oesophageal cancer: IntOGen driver in 1 cohort (ESCA)
- Hepatocellular carcinoma: IntOGen driver in 1 cohort (HCC)
- Gastric & gastro-oesophageal junction cancer: IntOGen driver in 1 cohort (STAD)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 3 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; CIViC holds 3 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: T-cell Acute Lymphoblastic Leukaemia; Childhood B-cell Acute Lymphoblastic Leukaemia; B-lymphoblastic Leukaemia/lymphoma, BCR-ABL1-like.
Latest papers
topQuery for this target: (TITLE:"IL7R" OR ABSTRACT:"IL7R" OR TITLE:"interleukin 7 receptor" OR ABSTRACT:"interleukin 7 receptor" OR TITLE:"Interleukin-7 receptor subunit alpha" OR ABSTRACT:"Interleukin-7 receptor subunit alpha" OR TITLE:"CD127" OR ABSTRACT:"CD127" OR TITLE:"IL7RA" OR ABSTRACT:"IL7RA" OR TITLE:"lnc-IL7R" OR ABSTRACT:"lnc-IL7R") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about IL7R, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetTAL1
Shares Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia.
- TargetCARD11
Shares Leukaemia (all types), Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types).
- TargetPAX5
Shares Leukaemia (all types), Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types).
- TargetJAK3
Shares Leukaemia (all types), Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types).
- TargetLEF1
Shares Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia.
- TargetTBL1XR1
Shares Leukaemia (all types), Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types).
- TargetRUNX1T1
Shares Leukaemia (all types), Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types).
- TargetTNFRSF14
Shares Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), CIViC.